On December 21, 2017, the U.S. Food and Drug Administration approved the use of hydroxyurea tablets in pediatric patients with sickle cell anemia to reduce the frequency of painful crises. To read more about this approval, please click on the link below:

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm